media – Page 44 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Novartis ‘ major new drug successfully completed Phase III

On August 11, Novartis announced that its anti-BAFF-R monoclonal antibody Ianalumab (VAY736) achieved the primary endpoint in two Phase III clinical trials in patients with Sjögren’s syndrome. Currently, there are no approved systemic therapies for Sjögren’s syndrome worldwide, and symptomatic treatments can only temporarily and partially relieve symptoms. Ianalumab is expected to end the history of Sjögren’s syndrome with no targeted drug available. Ianalumab is a novel, fully human monoclonal antibody targeting the B lymphocyte activating factor receptor (BAFF-R). It eliminates B cells through antibody-dependent cell-mediated cytotoxicity (ADCC) while simultaneously blocking BAFF-R-mediated B cell function and survival signals. The drug comes from Novartis’ partner Morphosys, which was acquired by Novartis for €2.7 billion in 2024. The drug is currently being developed for the treatment of a variety of B cell-driven autoimmune diseases, including Sjögren’s syndrome, immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), lupus nephritis (LN), warm antibody autoimmune hemolytic anemia ...
- Source: drugdu
- 82
- August 14, 2025
Hainan has issued policy measures to continuously increase support for the research and development of innovative drugs and medical devices

According to the website of the People’s Government of Hainan Province on August 14th, recently, the General Office of the People’s Government of Hainan Province issued the “Several Policy Measures of Hainan Province on Further Supporting the High-Quality Development of the Biomedical Industry”. The Policy Measures propose to continuously increase support for the research and development of innovative drugs and medical devices. Continue to implement the provincial biomedical industry research and development voucher policy. For the entire process of product research and development, including preclinical research, clinical trials, and industrialization of new achievements, provide financial rewards ranging from 400,000 to 10 million yuan based on phased achievements. The Policy Measures propose that enterprises both within and outside the province be encouraged to lawfully merge and restructure pharmaceutical enterprises in Hainan Province, revitalize assets on the spot and grow stronger. A 50% interest subsidy will be provided for bank loans arising ...
- Source: drugdu
- 81
- August 14, 2025
Freeze-dried Hib vaccine has been approved for clinical trials for the prevention of various invasive infections

Zhongzheng Intelligent Finance News Hualan Vaccine (301207) announced on the evening of August 13 that it has recently received the “Notice of Approval for Drug Clinical Trials” issued by the National Medical Products Administration for its freeze-dried Haemophilus influenzae type b conjugate vaccine (Hib vaccine). Agree to conduct clinical trials of this vaccine for the prevention of invasive infections caused by Haemophilus influenzae type b, including meningitis, pneumonia, sepsis, etc. It is reported that approximately 95% of invasive diseases caused by Haemophilus influenzae are triggered by type b strains. The Hib vaccine developed by the company is composed of purified Hib capsular polysaccharides combined with tetanus toxoid protein, and is in a freeze-dried dosage form. After vaccination, it can induce an immune response against Hib to provide protection. In addition, this vaccine is a component of the combined vaccine based on the component DPT that the company is developing. The ...
- Source: drugdu
- 82
- August 14, 2025
CMEH Shenzhen

Organiser:China Healthcare Industry Association, Chinese Medical Exchange Association Time：December 10-12, 2025 address：No.1 Zhancheng Road, Heping Community, Fuhai Subdistrict, Bao’an District, Shenzhen City, Guangdong Province Exhibition hall：Shenzhen International Convention and Exhibition Center (Bao’an New Venue) Product range: Medical Imaging: CT, DR, medical X-ray systems, ultrasonic diagnostic instruments, magnetic resonance equipment, tumor treatment machines, medical films and processing systems, etc. Remote Mobile Intelligent Monitoring Medical Devices: Sleep monitors, remote electrocardiogram (ECG), blood pressure, blood oxygen, and body temperature monitoring devices, cloud blood pressure monitors, Bluetooth blood pressure and glucose monitors, wearable medical devices, and health cabins, etc. Diagnostic and Therapeutic Equipment: Endoscopic systems, otorhinolaryngological treatment instruments, dynamic analysis instruments, cryogenic freezing equipment, dialysis treatment equipment, emergency medical equipment, surgical instruments, electrosurgical units and consumables, laser surgical instruments, ultrasonic surgery devices, etc. Ward Care Equipment and Appliances: Beds, carts, tables, cabinets, racks, etc. (The copyright of this content belongs to JUZHAN. Without ...
- Source: drugdu
- 245
- August 14, 2025
New medical insurance policy supports innovative drug CAR-T to bring breakthrough therapeutic effects and create diversified payment models

Recently, the National Healthcare Security Administration issued the “Several Measures to Support the High Quality Development of Innovative Drugs”, which clarifies the full chain support for the development of innovative drugs from research and development, admission, payment, etc. In this context, cell therapy, as a highly breakthrough innovative therapy in the field of biomedicine, is expected to further enhance the accessibility and affordability of its products. The Measures propose to encourage innovative drugs to conduct real-world research and link research results with medical insurance admission and renewal, promoting the application of real-world data in medical insurance admission. Of the 91 new drugs newly included in the medical insurance catalog in 2024, 33 were approved, launched, and included in the catalog that year, and innovative drugs are accelerating their integration into the medical insurance system. The clinical data accumulated through real-world research can more comprehensively verify the efficacy and safety of ...
- Source: drugdu
- 199
- August 13, 2025
Quadrivalent influenza vaccine Huierkangxin has been shortlisted for the initial review of the National Medical Insurance Innovation Catalogue.

Zhongzheng Smart Finance News: Zhuhai Zhuhui Biological – B (02627) announced in the morning of August 13 that according to the announcement of the National Healthcare Security Administration on August 12, the company’s quadrivalent influenza virus subunit vaccine, Huier Kangxin, has been included in the preliminary review list of innovative drugs for commercial health insurance in the country this year. It is the only vaccine product on the list. This vaccine was approved for marketing by the National Medical Products Administration in May 2023 and is suitable for people aged three and above (with a hemagglutinin concentration of 15μg/0.5ml for the virus strain). It is the first and only quadrivalent influenza virus subunit vaccine in China, providing broad protection against influenza viruses of type A H1N1, H3N2 and type B Yamagata and Victoria. The product is an optimized and upgraded version of traditional split vaccines, featuring comprehensive protection, high antigen ...
- Source: drugdu
- 155
- August 13, 2025
Roche terminates 12.2 billion yuan collaboration

Recently, Genentech, a subsidiary of Roche, announced the termination of its cooperation agreement with Bicycle Therapeutics. This decision will officially take effect in August. Genentech has had an exclusive partnership with Bicycle since February 2020, when Bicycle received a down payment of $30 million and is expected to receive a total transaction value of up to $1.7 billion (approximately RMB 12.2 billion) after Genentech reaches certain R&D milestones. However, the cooperation failed to proceed smoothly. Since 2023, Genentech has successively terminated several projects in the cooperation, until now it has completely stopped the cooperation. The reasons for the termination of the collaboration include, on the one hand, Genentech’s readjustment of project priorities and its gradual reduction of investment in Bicycle’s projects. On the other hand, Bicycle’s technology platform has certain limitations. Peptide screening is more difficult than antibody screening, and its shorter half-life limits development efficiency. Compared to antibody-drug conjugates ...
- Source: drugdu
- 118
- August 13, 2025
Hisense obtains approval to conduct clinical trials of HSK47977 tablets

August 12, Hisense(002653) announced that the company recently received the “Notice of Approval for Drug Clinical Trial” issued by the National Medical Products Administration, approving its independently developed innovative drugHSK47977 tablets are undergoing clinical trials. This drug is an oral BCL6 PROTAC small molecule formulation, primarily used to treat non-Hodgkin’s lymphoma, and meets the relevant drug registration requirements. HSK47977 tablets have no clinically active drugs targeting the same target in China, and they hold the potential to become a first-in-class product. The company completed Pre-IND discussions with the FDA in July 2025 and submitted an IND application, with the potential for simultaneous development in China and the US. Preclinical studies have demonstrated potent anti-tumor activity and a favorable safety profile, demonstrating high development potential. In the first quarter of 2025, Hisense achieved revenue of 892 million yuan and net profit attributable to shareholders of the parent company of 46.61 million ...
- Source: drugdu
- 115
- August 13, 2025
New Vaccine May Help Stop Deadly Pancreatic Cancers From Coming Back

TUESDAY, Aug. 12, 2025 (HealthDay News) — A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small clinical trial suggests. Pancreatic cancer is one of the most lethal cancers, with a five-year survival rate of about 13%, according to the American Cancer Society. Further, up to 80% of cases return after treatment, the National Institutes of Health says. “If you were to ask me what disease most needs something to prevent recurrences, I’d say this one,” Dr. Zev Wainberg, a leader of the trial, told NBC News. He’s co-director of the University of California, Los Angeles, gastrointestinal oncology program. The experimental vaccine targets KRAS gene mutations, which are found in about 25% of all cancers, the University of Texas MD Anderson Cancer Center says. This includes up to 90% of pancreatic cancers and roughly 40% of colon cancers. While ...
- Source: drugdu
- 112
- August 13, 2025
FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

The FDA has approved Insmed Incorporated’s Brinsupri (brensocatib), marking the first and only therapy indicated for non-cystic fibrosis bronchiectasis (NCFB) in adults and adolescents aged 12 years and older.1 FDA Approves Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis The regulatory action was based on positive results from the Phase III ASPEN (NCT04594369)2 and Phase II WILLOW trials (NCT03218917),3 both of which were published by The New England Journal of Medicine (NEJM).4,5 In these trials, Brinsupri was found to significantly reduce exacerbation rates, delay time to first flare, and preserve lung function compared to placebo. “The FDA approval of the first-ever treatment for non-cystic fibrosis bronchiectasis is a historic milestone for patients and for Insmed,” Martina Flammer, MD, MBA, Chief Medical Officer of Insmed, said in a press release. “By keeping patients at the center of everything we do, we have once again delivered a first-in-class medicine for a disease ...
- Source: drugdu
- 87
- August 13, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.